The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

Eli Lilly ( NYSE: LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's ( ...

The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the ...

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

People taking Eli Lilly’s obesity ... director of the Comprehensive Weight Control Center at Weill Cornell Medicine. “Two drugs together can produce better weight loss,” said Aronne, who ...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The importance of biosimilars only continues to ...

Most deal activity in the obesity and weight-loss sector is dominated by international big pharma, as companies race to sustain and expand their drug pipelines. 1. Eli Lilly purchased Versanis for ...